Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNM002 + tetanus vaccine
- Development stage
- Unknown
- Lead developer
- Trinomab Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
TNM002 is a first-in-class, fully human monoclonal antibody that specifically neutralizes tetanus toxin. It is developed using Trinomab’s proprietary HitmAb technology platform and is indicated for the emergency prevention of tetanus, particularly in patients at risk after exposure to Clostridium tetani due to traumatic injury. TNM002 acts by binding tightly to specific domains of the tetanus toxin, thereby neutralizing its neurotoxic effects and preventing it from disrupting inhibitory neurotransmission in the central nervous system. Compared with traditional plasma-derived products such as human tetanus immunoglobulin (HTIG) and equine antitoxin (TAT), TNM002 offers advantages including superior efficacy, longer-lasting protection, improved safety profile with low immunogenicity, and suitability for large-scale production[1][2][4][7]. The combination of TNM002 with adsorbed tetanus vaccine has been studied to assess pharmacokinetic/pharmacodynamic interactions and safety in healthy adults[6]. The primary indication is prophylaxis against tetanus.
- Brand names
- 新替妥
- Other names
- siltartoxatug
Beyond the preview
Go deeper on TNM002 + tetanus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNM002 + tetanus vaccine.